Krebs Biochemicals and Industries, a company in the Pharmaceuticals industry, reported revenue of ₹5.79 crore and a net loss of ₹5.40 crore for the September 2026 quarter.
Krebs Biochemicals and Industries (NSE: KREBSBIO) closed at ₹57.08 on 20 Nov 2026, down 15.2% over the past year. Its market capitalisation is ₹123 crore.
Incorporated in 1991, Krebs Biochemicals & Industries Ltd is presently engaged in manufacturing of active pharmaceutical ingredients.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.